BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Drug Discovery

"Innovation Down Under: Exploring the Australian BioPharma Industry"

Introduction Nestled on the vast, sunburned continent known for its stunning landscapes and unique wildlife, the Australian BioPharma industry has...

September 05, 2023 | Analysis

ABM Therapeutics Initiates Phase I Study of ABM-1310 in BRAF V600 Brain Tumors

ABM-1310, the company's proprietary clinical candidate developed as a next-generation BRAF inhibitor and demonstrated superior properties in pre-clinical a...

September 04, 2023 | News

South Korea's Genexine's Long-Acting Growth Hormone Meets Phase 3 Endpoint

Phase 3 clinical trial in China meets primary endpoint On track to file BLA in China in 2024 The study being conducted by Genexine’s partner in...

August 31, 2023 | News

Menarini's ELZONRIS® (Tagraxofusp) Receives Orphan Drug Designation for BPDCN by Japanese Ministry of Health

The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-own...

August 31, 2023 | Regulatory

Epigenic Therapeutics Raises $32M for Breakthrough Epigenome Medicine Development

This round of financing will support the preclinical development and early clinical validation of two leading programs, discovery of future pipelines, expa...

August 30, 2023 | News

BOC Sciences Introduces a Novel XDC Bioconjugation Platform to Advance Biomedical Research

The newly developed XDC bioconjugation platform offered by BOC Sciences introduces a range of advanced technologies and optimized protocols, revolutionizin...

August 25, 2023 | News

Sanyou and Sinorda Partner for Innovative Drug Research

According to the cooperation agreement, leveraging Sanyou's world-leading core technology platform for integrated R&D and preclinical development of in...

August 23, 2023 | News

CanariaBio's MAb-AR20.5 for Pancreatic Cancer Granted FDA Orphan Drug Designation

CanariaBio Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative immunotherapies for cancer, anno...

August 22, 2023 | News

Everest Medicines' Partner Calliditas Therapeutics Gets FDA Priority Review for Nefecon® in IgA Nephropathy

"We congratulate our partner Calliditas for being granted priority review by the FDA for full approval and taking a step closer to offering this first-in-d...

August 22, 2023 | Regulatory

Verily and OneOncology Announce Collaboration to Advance Cancer Research

Verily, an Alphabet precision health technology company, and OneOncology, the national platform for independent oncology practices, have established a stra...

August 17, 2023 | News

Daewoong Pharmaceutical Introduces 'Fexuprazan' with Global Export to the Philippines

Daewoong Pharmaceutical (CEO Jeon Seng-ho, Lee Chang-jae) announced that 'Fuxuprazan' is officially launched in the Philippines o...

August 17, 2023 | News

Parexel & Partex Unite Artificial Intelligence and Big Data to Speed Drug Discovery

Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, a...

August 16, 2023 | News

FDA Grants Priority Review for Cefepime-Taniborbactam to Treat cUTI

Everest Medicines (HKEX 1952.HK)'s partner Venatorx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted the company's N...

August 16, 2023 | News

Kelun-Biotech's Phase III Trial of SKB264 Meets Endpoint in Advanced TNBC

Kelun-Biotech recently held an Independent Data Monitoring Committee (IDMC) meeting to review the interim analysis data of the Phase III clinical trial of ...

August 15, 2023 | News

Stay Connected